What's Happening?
Novartis has received approval from the European Commission for Itvisma, a new intrathecal formulation of its spinal muscular atrophy (SMA) gene therapy, onasemnogene abeparvovec. This approval allows the treatment to be used in a broader patient population,
including individuals from the age of two upwards, extending to adults. Previously, the intravenous version, Zolgensma, was limited to babies and young children under a certain weight due to potential liver side effects. Itvisma, administered directly into the cerebrospinal fluid, circumvents these issues, offering a one-time treatment option for older patients. The approval is based on successful phase 3 trials, STEER and STRENGTH, which demonstrated efficacy in patients who had not walked independently. This development is seen as a significant milestone for the SMA community, providing new treatment options for patients and families.
Why It's Important?
The approval of Itvisma in Europe represents a significant advancement in the treatment of SMA, a genetic neuromuscular disease. It offers a new therapeutic option for older patients who previously had limited choices, potentially reducing the need for lifelong treatments like Biogen's Spinraza and Roche's Evrysdi. For Novartis, this expansion could lead to substantial financial gains, with the company projecting 'multibillion-dollar' sales. The broader patient eligibility in Europe follows a similar approval in the U.S., indicating a growing market for this gene therapy. This development not only enhances treatment accessibility but also underscores the importance of innovative gene therapies in addressing complex genetic disorders.
What's Next?
Following the EU approval, Novartis will focus on national reimbursement negotiations to determine launch timings and pricing across Europe. The company aims to ensure timely and equitable access to Itvisma for patients. As the eligible patient pool for the intravenous version of the therapy diminishes, Novartis is likely to concentrate on expanding the reach of Itvisma. The company will also monitor the market response and adjust its strategies to maximize the therapy's impact and sales potential. Patient advocacy groups will likely continue to push for broader access and affordability of this treatment across different regions.
